SKIN CANCER WEBINARS

You have questions about skin cancer? We have answers. Enjoy on-demand content or participate in a live question-and-answer session with top experts in the field of dermatology and oncology.

 

Living With Skin Cancer – Live Q/A – September 27, 2021  7:00 pm ET

In this live, 45-minute webinar, Krista M. Rubin, RN, MS, FNP-BC, Nurse Practitioner at the Center for Melanoma, Massachusetts General Hospital Cancer Center, discusses various aspects of living with skin cancer. She’ll answer your questions live!  Ms Rubin will cover topics such as:

  • Risk for additional skin cancer
  • Heredity of skin cancer
  • Scar care
  • Managing anxiety
  • Follow-up strategies

NEW! Living With Skin Cancer Q/A

Krista M. Rubin, RN, MS, FNP-BC, Nurse Practitioner at the Center for Melanoma, Massachusetts General Hospital Cancer Center, answers questions posed by patients about living with skin cancer. View all the videos or select those that are most relevant to you.

 

Risk of additional skin cancers in a skin-cancer patient

 

Chances of a non-melanoma skin cancer converting to a melanoma

 

Basal cell and squamous cell skin cancers and risk for melanoma

 

Why most non-melanoma skin cancers are managed by dermatologists, not oncologists

 

Skin-cancer heredity and the likelihood of passing the risk for skin cancer on to your children

 

Follow-up visits for skin cancer

 

Skin self-check and what a recurrence might look like

 

Non-melanoma skin cancers and sun safety

 

Anxiety regarding the skin-cancer diagnosis and strategies to combat it

 

Dietary changes to reduce the risk for additional skin cancer(s) or skin-cancer recurrence

 

Strategies to minimize the scar after skin-cancer surgery

Webinar Faculty

 

Krista M. Rubin, RN, MS, FNP-BC

Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Krista Rubin is a nurse practitioner in the Center for Melanoma at Massachusetts General Hospital. For the past 20 years, her clinical practice has focused extensively on skin cancer. In her clinical practice, Ms Rubin has provided care to patients receiving immunotherapy, targeted therapy, and various investigational agents. Ms Rubin has served as a sub-investigator for more than 100 clinical research protocols, including many of the pivotal trials that led to the FDA approval of such agents as interleukin-2, interferon alfa-2b, ipilimumab, pembrolizumab, nivolumab, trametinib, dabrafenib, and vemurafenib. She continues to work with these agents in her current clinical setting. She is considered an expert in the areas of skin cancer education and prevention, cancer immunotherapy, targeted therapy, and symptom management.

Ms Rubin has authored or co-authored numerous articles in peer reviewed journals on various topics related to skin cancer. She has consulted, served on numerous planning committees, and continues to be a sought-after speaker at local, regional, national, and international conferences. She sits on the Medical Advisory Board for IMPACT Melanoma (formerly Melanoma Foundation of New England) and the Melanoma Research Foundation’s Pediatric Melanoma Committee. She served for a decade on the Board of Directors for the Children’s Melanoma Prevention Foundation. She is Nurse Liaison to the Melanoma Committee for the Eastern Cooperative Oncology Group (ECOG), of which she has been a member since 2002. She is a member of the Society of Immunotherapy in Cancer (SITC), the Oncology Nursing Society (ONS), the Dermatology Nurses’ Association (DNA), and the American Society of Clinical Oncology (ASCO).

Ms Rubin was the recipient of the 2010 award for Excellence in Cancer Prevention and Early Detection from the Oncology Nursing Society and was the recipient of the 2014 award for Outstanding Community Service from the Dermatology Nurses’ Association.

 

Skin Cancer: Ask-the-Experts Webinar Archive

Check out the archive from the Skin Cancer: Ask the Experts Webinar. In this ½ hour video, dermatologic surgeon John A Carucci, MD, PhD, and medical oncologist Anna Pavlick, DO, answer questions about the management of nonmelanoma skin cancer. Learn about:

  • Recognizing side effects of immunotherapy and taking action early
  • Actinic keratoses, their management, and the risk for skin cancer
  • The role of clinical trials for advanced squamous cell skin cancer
  • How to select the best treatment option for advanced squamous cell skin cancer
  • Basal cell carcinoma, squamous cell skin cancer, and melanoma in people with dark skin
  • The role of a second opinion
  • Heredity of nonmelanoma skin cancer
  • Skin cancers in solid organ transplant patients

Frequently Asked Questions in Skin Cancer

In this archived section, Dr John A. Carucci, MD, PhD, Dermatologic Surgeon at NYU Langone Health, and Anna Pavlick, DO, Medical Oncologist at Weill Cornell Medicine, answer questions posed by patients about the management of nonmelanoma skin cancers. You can view the entire below.

You can access the video below. Once you enter the video, please enter your first name, last name, and email. Once we have your information, we will be able to send you a notification when the Q/A session is scheduled.

 

Webinar Faculty

John A. Carucci, MD, PhD

Dr Carucci is a professor in the Ronald O. Perelman Department of Dermatology at New York University Grossman School of Medicine and Director of Dermatologic Surgery at NYU Langone Health, New York, NY.  He received both his medical degree and his PhD from SUNY Downstate College of Medicine, Brooklyn, NY. He completed his dermatology residency at NYU, after which he pursued a fellowship in dermatologic surgery at Yale–New Haven Medical Center. He currently serves as President of the International Immunosuppression & Transplant Skin Cancer Collaborative. Dr Carucci specializes in reconstructive  surgery using Mohs and laser techniques, particularly for those diagnosed with squamous cell carcinoma. His most recent research has focused on the interaction of the immune system with skin cancers, specifically the role of interleukin-22–producing cells in promoting the development of squamous cell carcinoma. Further research holds the possibility of identifying practical regulatory targets within the IL-22 pathway that could ultimately lead to strategies for blocking tumor development. In addition, Dr Carucci and his collaborators have developed a method of correlating gene expression with the clinical course of squamous cell carcinoma.

Anna Pavlick, BSN, MSc, DO, MBA

Anna Pavlick, BSN, MSc, DO, MBA, is a medical oncologist with more than 20 years of experience treating patients with skin cancer, including basal cell and squamous cell carcinoma, melanoma, and Merkel cell carcinoma. She is also an expert in treating ocular melanoma, eyelid tumors, and other rare solid tumor malignancies. Dr Pavlick earned her medical degree from the University of Medicine and Dentistry of New Jersey (UMDNJ)–Robert Wood Johnson Medical School; her Master of Science in human anatomy from Fairleigh Dickinson University; and her Bachelor of Science in biology and nursing from Fairfield University. She completed an internal medicine residency at UMDNJ and hematology and oncology fellowship training at Memorial Sloan Kettering Cancer Center, after which she joined the faculty of Weill Cornell Medicine, New York, NY, as Professor of Medicine in the Division of Hematology & Medical Oncology. She is the founding Director of the Cutaneous Oncology Program there and at New York-Presbyterian Hospital. Dr Pavlick’s major research interests include investigating targeted therapies, combination therapies, and immunotherapies.